<DOC>
	<DOCNO>NCT01235741</DOCNO>
	<brief_summary>Following screening , eligible subject enrol 6‑week Low Calorie Diet ( LCD ) lead-in period . Subjects lose least 2 % body weight end 6-week LCD lead-in period randomize 1 2 treatment arm ( pramlintide+metreleptin placebo ) begin 16-week treatment period effect body weight treatment pramlintide+metreleptin compare placebo . Following 16 week blind core treatment period , subject discontinue study medication period 12 week . Following 12 week off-drug follow-up period , subject group initiate 12 week open-label treatment period Pramlintide+Metreleptin . During 12 week off-drug 12 week open label treatment period , subject continue participate Lifestyle Intervention ( LSI ) program .</brief_summary>
	<brief_title>A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is obese BMI ≥35 ≤45 kg/m2 . Has stable body weight ( vary &gt; 5 % within 3 month prior study start ) . Meets certain requirement respect concomitant medication . Has smoke use nicotinecontaining product least 12 month prior study start . Has enrol weight loss program within 2 month prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pramlintide</keyword>
	<keyword>Metreleptin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Amylin</keyword>
	<keyword>Takeda</keyword>
</DOC>